As Head of Dermatology at Hospital Clínic de Barcelona and Professor at the University of Barcelona, I have dedicated my career to advancing dermatological research with a focus on melanoma. In my role as the leader of IDIBAPS "Melanoma: Imaging, Genetics, and Immunology" research group and CIBERER, I've overseen more than 30 competitive research projects, funded by national and international agencies like Horizon Europe, FEDER, and ISCIII. In addition to this, I have also served as Principal Investigator for over 50 projects funded by the pharmaceutical industry, further contributing to the development of innovative treatments and therapies in dermatology. Currently, I am coordinating the MELCAYA project, a collaborative endeavor involving 20 international partners and a budget of 8 million. I've contributed to over 600 peer reviewed scientific publications and collaborated extensively with pharmaceutical companies, including BMS, Merk, Sanofi, Novartis, Pfizer, and Roche, participating in more than 70 clinical trials aimed at improving patient outcomes.

My educational role extended from being associated professor at the University of Barcelona from 2012, to being Professor since 2020, involved in pregraduated and postgraduated teaching including participation in several master degrees. Beyond the classroom, I've supervised 44 theses, doctoral (19) and master's projects (25). I am in the executive board of the EORTC-Melanoma Group, of the GEM (Grupo Español Multidisciplinar de Melanoma), the International Dermoscopy Society (IDS), The International Confocal Working Group and the Asociación Española de Investigación en Cancer (ASEICA). I am the co-founder of Athena Tech, a spin-off company, and hold two patents in dermatology. 

A key component of my work is international collaboration. I am actively involved in global research consortia such as Genomel, Melanostrum, Biogenomel and ISIC among others. My team is interdisciplinary, consisting of clinical researchers, basic researchers, and AI engineers. One of the focal areas of our current research is to understand the mechanisms of response to new immunotherapy protocols, especially those related to PD-1/PD-L1 inhibitors. My career embodies a relentless pursuit of translational research in dermatology, marked by spearheading groundbreaking projects and international collaborations. Beyond this, I have been a vanguard in integrating artificial intelligence into healthcare, thus fostering innovation that not only advances medical science but also transforms patient care, healthcare services, and educational paradigms. This multipronged contribution has had a profound impact on enhancing the quality of life for patients.